Advantage Energy (TSE:AAV – Free Report) (NYSE:AAV) had its price target hoisted by Raymond James from C$11.00 to C$13.00 in a research note issued to investors on Friday, BayStreet.CA reports. Raymond James currently has an outperform rating on the stock. Several other research analysts have also recently issued reports on AAV. National Bank Financial decreased […]
In its second big pharma deal to date, Shape Therapeutics Inc. drew Otsuka Pharmaceutical Co. Ltd. to the table in a potential $1.5 billion-plus collaboration initially aimed at developing gene therapies for ocular diseases. The multitarget agreement, which includes options for additional targets and tissue types, will combine Shape’s AI-driven adeno-associated virus (AAV) platform and Otsuka’s expertise in ophthalmology to develop intravitreally delivered AAV therapies.
Desjardins set a C$13.50 price objective on Advantage Energy (TSE:AAV – Free Report) (NYSE:AAV) in a report published on Tuesday morning, BayStreet.CA reports. The firm currently has a buy rating on the stock. A number of other brokerages have also recently commented on AAV. BMO Capital Markets cut Advantage Energy from an outperform rating to […]